GR3031919T3 - PEPTIDES OF HUMAN p53 PROTEIN FOR USE IN HUMAN T CELL RESPONSE INDUCING COMPOSITIONS, AND HUMAN p53 PROTEIN-SPECIFIC CYTOTOXIC T-LYMPHOCYTES. - Google Patents
PEPTIDES OF HUMAN p53 PROTEIN FOR USE IN HUMAN T CELL RESPONSE INDUCING COMPOSITIONS, AND HUMAN p53 PROTEIN-SPECIFIC CYTOTOXIC T-LYMPHOCYTES.Info
- Publication number
- GR3031919T3 GR3031919T3 GR990403009T GR990403009T GR3031919T3 GR 3031919 T3 GR3031919 T3 GR 3031919T3 GR 990403009 T GR990403009 T GR 990403009T GR 990403009 T GR990403009 T GR 990403009T GR 3031919 T3 GR3031919 T3 GR 3031919T3
- Authority
- GR
- Greece
- Prior art keywords
- human
- protein
- pct
- lymphocytes
- peptides
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 230000005867 T cell response Effects 0.000 title 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 title 1
- 230000001939 inductive effect Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 abstract 3
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 abstract 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 238000003556 assay Methods 0.000 abstract 1
- 238000002405 diagnostic procedure Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000006698 induction Effects 0.000 abstract 1
- 230000002018 overexpression Effects 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP92201510 | 1992-05-26 | ||
PCT/NL1993/000102 WO1993024525A1 (en) | 1992-05-26 | 1993-05-18 | PEPTIDES OF HUMAN p53 PROTEIN FOR USE IN HUMAN T CELL RESPONSE INDUCING COMPOSITIONS, AND HUMAN p53 PROTEIN-SPECIFIC CYTOTOXIC T-LYMPHOCYTES |
EP93913627A EP0643726B1 (en) | 1992-05-26 | 1993-05-18 | PEPTIDES OF HUMAN p53 PROTEIN FOR USE IN HUMAN T CELL RESPONSE INDUCING COMPOSITIONS, AND HUMAN p53 PROTEIN-SPECIFIC CYTOTOXIC T-LYMPHOCYTES |
Publications (1)
Publication Number | Publication Date |
---|---|
GR3031919T3 true GR3031919T3 (en) | 2000-03-31 |
Family
ID=8210629
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GR990403009T GR3031919T3 (en) | 1992-05-26 | 1999-11-19 | PEPTIDES OF HUMAN p53 PROTEIN FOR USE IN HUMAN T CELL RESPONSE INDUCING COMPOSITIONS, AND HUMAN p53 PROTEIN-SPECIFIC CYTOTOXIC T-LYMPHOCYTES. |
Country Status (11)
Country | Link |
---|---|
US (1) | US5679641A (el) |
EP (1) | EP0643726B1 (el) |
JP (2) | JPH08501280A (el) |
AT (1) | ATE183514T1 (el) |
AU (1) | AU681853B2 (el) |
CA (1) | CA2136624A1 (el) |
DE (1) | DE69326064T2 (el) |
DK (1) | DK0643726T3 (el) |
ES (1) | ES2139012T3 (el) |
GR (1) | GR3031919T3 (el) |
WO (1) | WO1993024525A1 (el) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1421947A1 (en) * | 1992-07-22 | 2004-05-26 | The Trustees Of Princeton University | p53 vaccine |
FR2698367B1 (fr) * | 1992-11-02 | 1995-02-17 | Eurobio Lab | Fragments de la protéine p53 et leurs utilisations dans la détection et le suivi d'états pathologiques. |
KR960700739A (ko) * | 1993-03-05 | 1996-02-24 | 카린 이스텀 | Hla-a2. 1 결합 펩티드 및 그의 용도(hla-a2. 1 binding peptides and their uses) |
WO1995004817A1 (en) * | 1993-08-06 | 1995-02-16 | Cytel Corporation | Methods for ex vivo therapy using peptide-loaded antigen presenting cells for the activation of ctl |
FR2722207B1 (fr) * | 1994-07-07 | 1996-09-27 | Inst Nat Sante Rech Med | Methode pour generer une population de cellules presentant a leur surface une forte densite d'un pepride exogene specifique associe azx molecules du cmh; population de cellules |
JPH10510988A (ja) | 1994-12-14 | 1998-10-27 | ザ スクリップス リサーチ インスティテュート | 腫瘍−特異的細胞毒性t細胞のインビボ活性化 |
US5925799A (en) * | 1996-03-12 | 1999-07-20 | Abb Lummus Global Inc. | Catalytic distillation and hydrogenation of heavy unsaturates in an olefins plant |
US6458354B1 (en) | 1996-03-28 | 2002-10-01 | The Johns Hopkins University | Molecular complexes which modify immune responses |
EP0889964A1 (en) * | 1996-03-28 | 1999-01-13 | The Johns Hopkins University | Soluble divalent and multivalent heterodimeric analogs of proteins |
US6218363B1 (en) * | 1996-08-28 | 2001-04-17 | Thomas Jefferson University | MHC peptides and methods of use |
SE9604581D0 (sv) * | 1996-12-12 | 1996-12-12 | Karolinska Innovations Ab | An agent against cancer and virus infections |
US6268411B1 (en) * | 1997-09-11 | 2001-07-31 | The Johns Hopkins University | Use of multivalent chimeric peptide-loaded, MHC/ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses |
CA2321026A1 (en) * | 1998-03-09 | 1999-09-16 | Zealand Pharmaceuticals A/S | Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis |
SE9801695D0 (sv) * | 1998-05-14 | 1998-05-14 | Karolinska Innovations Ab | Inhibition of p53 function by a p53-derived peptide |
DE69940774D1 (de) * | 1998-06-17 | 2009-06-04 | Idm Pharma Inc | Hla-bindende peptide und ihre verwendungen |
CA2367692A1 (en) * | 1999-03-15 | 2000-09-21 | Introgen Therapeutics, Inc. | Dendritic cells transduced with a wild-type self gene elicit potent antitumor immune responses |
TW410377B (en) * | 1999-06-17 | 2000-11-01 | Taiwan Semiconductor Mfg | Method of planarization and the apparatus of the same |
CA2383737C (en) * | 1999-09-08 | 2011-01-18 | Transgene S.A. | Muc-1 derived peptides |
FR2794368A1 (fr) * | 1999-10-07 | 2000-12-08 | Biovector Therapeutics | Fragments proteiques polyepitopiques, leur obtention et leurs utilisations notamment en vaccination |
CA2393662A1 (en) * | 1999-12-10 | 2001-06-14 | Epimmune Inc. | Inducing cellular immune responses to p53 using peptide and nucleic acid compositions |
JP4439808B2 (ja) * | 2000-06-05 | 2010-03-24 | アルター・バイオサイエンス・コーポレーション | T細胞レセプター融合体および結合体ならびにそれらの使用方法 |
DE10109855A1 (de) * | 2001-03-01 | 2002-09-12 | Stanislawski Thomas | Polypeptide eines p53-Protein-spezifischen murinen alpha/beta T-Zell Rezeptors, diese kodierende Nukleinsäuren und deren Verwendung |
AU2002316190B8 (en) * | 2001-06-05 | 2009-01-29 | Altor Bioscience Corporation | p53 binding T cell receptor molecules and uses thereof |
US7179784B2 (en) * | 2001-07-10 | 2007-02-20 | Massachusetts Institute Of Technology | Surfactant peptide nanostructures, and uses thereof |
WO2004006951A1 (en) * | 2002-07-12 | 2004-01-22 | The Johns Hopkins University | Reagents and methods for engaging unique clonotypic lymphocyte receptors |
CA2608236A1 (en) * | 2005-05-12 | 2006-11-23 | Introgen Therapeutics, Inc. | P53 vaccines for the treatment of cancers |
EP1933864A4 (en) * | 2005-09-07 | 2009-12-16 | Receptor Logic Ltd | ANTIBODIES AS T-CELL RECEPTOR MIMICS, METHOD OF MANUFACTURE AND ITS USES |
US20110053849A1 (en) * | 2006-08-17 | 2011-03-03 | Salomon Amar | Regulation of litaf modulated cytokine production by a novel p53 short peptide |
CA2677045C (en) | 2007-01-31 | 2016-10-18 | Dana-Farber Cancer Institute, Inc. | Stabilized p53 peptides and uses thereof |
AU2008232709C1 (en) | 2007-03-28 | 2015-01-15 | President And Fellows Of Harvard College | Stitched polypeptides |
SI2603600T1 (sl) | 2010-08-13 | 2019-04-30 | Aileron Therapeutics, Inc. | Peptidomimetični makrocikli |
TWI643868B (zh) | 2011-10-18 | 2018-12-11 | 艾利倫治療公司 | 擬肽巨環化合物 |
US8987414B2 (en) | 2012-02-15 | 2015-03-24 | Aileron Therapeutics, Inc. | Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles |
KR102112373B1 (ko) | 2012-02-15 | 2020-05-18 | 에일러론 테라퓨틱스 인코포레이티드 | 펩티드모방체 마크로사이클 |
AU2013337388B2 (en) | 2012-11-01 | 2018-08-02 | Aileron Therapeutics, Inc. | Disubstituted amino acids and methods of preparation and use thereof |
AU2015320545C1 (en) | 2014-09-24 | 2020-05-14 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and formulations thereof |
WO2016049359A1 (en) | 2014-09-24 | 2016-03-31 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
MX2017011834A (es) | 2015-03-20 | 2018-04-11 | Aileron Therapeutics Inc | Macrociclos peptidomimeticos y usos de los mismos. |
JP2018528217A (ja) | 2015-09-10 | 2018-09-27 | エルロン・セラピューティクス・インコーポレイテッドAileron Therapeutics,Inc. | Mcl−1のモジュレーターとしてのペプチド模倣大環状分子 |
KR20200065026A (ko) * | 2017-09-29 | 2020-06-08 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | P53 암-특이적 돌연변이에 대한 항원 특이성을 갖는 t 세포를 단리하는 방법 |
WO2020023502A1 (en) | 2018-07-23 | 2020-01-30 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
CN114651001A (zh) * | 2019-11-07 | 2022-06-21 | 武汉华大吉诺因生物科技有限公司 | 肿瘤免疫治疗多肽及其应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NO312681B1 (no) * | 1990-08-24 | 2002-06-17 | Univ California | Fremgangsmåte for fremstilling av en farmasöytisk blanding med suppresiv virkning/aktivitet |
-
1993
- 1993-05-18 CA CA002136624A patent/CA2136624A1/en not_active Abandoned
- 1993-05-18 AT AT93913627T patent/ATE183514T1/de not_active IP Right Cessation
- 1993-05-18 DK DK93913627T patent/DK0643726T3/da active
- 1993-05-18 US US08/338,634 patent/US5679641A/en not_active Expired - Fee Related
- 1993-05-18 JP JP6500408A patent/JPH08501280A/ja active Pending
- 1993-05-18 ES ES93913627T patent/ES2139012T3/es not_active Expired - Lifetime
- 1993-05-18 EP EP93913627A patent/EP0643726B1/en not_active Expired - Lifetime
- 1993-05-18 AU AU43591/93A patent/AU681853B2/en not_active Ceased
- 1993-05-18 WO PCT/NL1993/000102 patent/WO1993024525A1/en active IP Right Grant
- 1993-05-18 DE DE69326064T patent/DE69326064T2/de not_active Expired - Fee Related
-
1999
- 1999-11-19 GR GR990403009T patent/GR3031919T3/el unknown
-
2003
- 2003-07-09 JP JP2003194583A patent/JP2004123708A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
AU681853B2 (en) | 1997-09-11 |
EP0643726B1 (en) | 1999-08-18 |
AU4359193A (en) | 1993-12-30 |
ATE183514T1 (de) | 1999-09-15 |
JPH08501280A (ja) | 1996-02-13 |
WO1993024525A1 (en) | 1993-12-09 |
DE69326064D1 (de) | 1999-09-23 |
EP0643726A1 (en) | 1995-03-22 |
JP2004123708A (ja) | 2004-04-22 |
US5679641A (en) | 1997-10-21 |
CA2136624A1 (en) | 1993-12-09 |
DE69326064T2 (de) | 2000-05-25 |
ES2139012T3 (es) | 2000-02-01 |
DK0643726T3 (da) | 2000-03-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GR3031919T3 (en) | PEPTIDES OF HUMAN p53 PROTEIN FOR USE IN HUMAN T CELL RESPONSE INDUCING COMPOSITIONS, AND HUMAN p53 PROTEIN-SPECIFIC CYTOTOXIC T-LYMPHOCYTES. | |
IL105554A0 (en) | Peptides of human papilloma virus for use in human t cell response inducing compositions | |
ATE415173T1 (de) | Pan dr-bindeproteinen zur erhöhung der immunantwort | |
UA66417C2 (en) | Recombinant adenovirus affecting canines, pharmaceutical composition | |
HK1019856A1 (en) | Therapeutic uses of bpi protein products for human meningococcemia | |
TR199501630A2 (tr) | Peptid p277 benzerleri ve diagnoz ve dibetlerin'lerin tedavisi icin onlari iceren kompozisyonlar. | |
EP1071443A4 (en) | ISOLATED PEPTIDES CORRESPOND THE NY-ESO-1 AMINO ACID SEQUENCES AND BIND TO MHC CLASS I AND MHC CLASS II MOLECULES AND THEIR USE | |
ATE63126T1 (de) | Tetra- und penta-peptide mit der sequenz lysylarginyl-aspartyl, und ihre verwendung als antithrombotika. | |
GR3035152T3 (en) | Methods for detection and treatment of individuals having abnormal cells expressing hla-a2/tyrosinase peptide antigens | |
CA2184175A1 (en) | Isolated, tyrosinase derived peptides and uses thereof | |
FR2724320B1 (fr) | Nouvel implant pour le traitement des maladies acquises | |
NO964561L (no) | Tri-, tetra-, penta-, og polypeptider, og bruken av disse som antidepressiv agent | |
GR3001922T3 (en) | Use of n,n'-bis-l-amino acid-l-cystin peptides in amino acid preparations for oral and parenteral administration | |
KR100488038B1 (ko) | 기관 보호 활성을 지닌 신규한 신체 보호 화합물 펩티드염, 이의 제조 방법 및 치료에서의 이의 용도 | |
TR199700842T1 (xx) | �nsan DNase I Varyantlar�. | |
BR0014803A (pt) | Peptìdeo, composição farmacêutica, uso de um ou mais dos peptìdeos, e, composição de diagnóstico | |
NZ335136A (en) | Isolated peptides which complex with hla-cw*16 molecules, and uses thereof | |
AU1318797A (en) | Peptides and uses thereof for therapy of celiac diseases | |
DE3462692D1 (en) | Pharmacologically active peptides | |
FR2694938B1 (fr) | Nouveaux peptides, anticorps diriges contre ces peptides, anticorps anti-idiotypiques, application a titre de medicaments, compositions pharmaceutiques et kits de diagnostic les renfermant. | |
BG101846A (en) | HUMAN DNase I VARIANTS | |
ATE293163T1 (de) | Cyclin e spezifische konstrukte und komplexe | |
IL127080A0 (en) | The use of peptides derived from zona pelucida proteins for contraception and pharmaceutical compositions containing the same | |
CA2247998A1 (en) | Fragments of cr1 and their use | |
UA9703A (uk) | Антипротеіназний засіб |